Journal of Cellular and Molecular Medicine · Nov 8, 2026

Integrated Multi‐Omics Analyses Reveal Causal DNA Methylation‐Breast Cancer Associations Mediated by Plasma Proteins

By Wang W, Cheng Z, Liu R et al.

Although aberrant DNA methylation is implicated in breast cancer (BC) pathogenesis, establishing causality is difficult and the downstream mediators are unclear. We investigated the causal role of blood DNA methylation and its proteomic mediators. Differentially methylated positions (DMPs) were identified from a genome‐wide blood methylation dataset, and two‐sample Mendelian randomization (MR) was performed using methylation quantitative trait loci for the significant DMPs together with BC genetic data from two independent consortia (FinnGen and the Breast Cancer Association Consortium), applying inverse‐variance weighted and generalized summary‐data‐based MR with validation by Bayesian colocalization and PheWAS. Proteome‐wide mediation and single‐cell RNA sequencing (scRNA‐seq) analyses explored downstream pathways. We identified 19,169 DMPs, and MR revealed 95 CpG sites with consistent, MR‐supported associations with BC. Meta‐analysis confirmed three high‐confidence loci (cg15146122, OR = 0.91; cg01529201, OR = 1.14; cg24704912, OR = 1.11), with colocalization support for two of them. Mediation analysis identified 203 BC ‐associated proteins, the three CpG sites influencing 41‐314 proteins involved in immune regulation, apoptosis and lysosomal pathways and scRNA‐seq localized the mediator proteins to specific cell populations of the tumour microenvironment. Blood DNA methylation is therefore associated with BC risk in an MR‐supported manner through specific plasma proteins, highlighting candidate epigenetic biomarkers.

doi.org/10.1111/jcmm.71424Open accessPubMed 43000987Mechanisms

AgingResearch.News